ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3021% above fair value
$10.75+0.53 (+5.19%)
Close on Nov 13, 2026Market cap $97.63MP/E 53.8Yield –
ImmuCell r&d expenses
Research and development expenses are spending on new products and technology.
ImmuCell's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.37M, down 55.7% year over year. For fiscal 2025 it was $3.04M, down 22.0% from the year before. Over ten years it grew 9.4% a year on average. The highest annual figure on record is $4.49M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.04M | -22.0% |
| FY2024 | Dec 31, 2024 | $3.90M | -11.3% |
| FY2023 | Dec 31, 2023 | $4.39M | -2.2% |
| FY2022 | Dec 31, 2022 | $4.49M | +7.8% |
| FY2021 | Dec 31, 2021 | $4.17M | -4.3% |
| FY2020 | Dec 31, 2020 | $4.35M | +18.1% |
| FY2019 | Dec 31, 2019 | $3.69M | +4.9% |
| FY2018 | Dec 31, 2018 | $3.52M | +71.8% |
| FY2017 | Dec 31, 2017 | $2.05M | +64.5% |
| FY2016 | Dec 31, 2016 | $1.24M | +0.7% |
| FY2015 | Dec 31, 2015 | $1.24M | -43.3% |
| FY2014 | Dec 31, 2014 | $2.18M | +88.8% |
| FY2013 | Dec 31, 2013 | $1.15M | +25.8% |
| FY2012 | Dec 31, 2012 | $917.60K | -46.7% |
| FY2011 | Dec 31, 2011 | $1.72M | +15.2% |
| FY2010 | Dec 31, 2010 | $1.49M | -9.2% |
| FY2009 | Dec 31, 2009 | $1.64M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $176.77K | -74.5% |
| Q2 FY2026 | Jun 30, 2026 | $119.65K | -85.6% |
| Q1 FY2026 | Mar 31, 2026 | $317.69K | -58.0% |
| Q4 FY2025 | Dec 31, 2025 | $758.86K | -7.4% |
| Q3 FY2025 | Sep 30, 2025 | $694.31K | -11.7% |
| Q2 FY2025 | Jun 30, 2025 | $831.86K | -19.3% |
| Q1 FY2025 | Mar 31, 2025 | $756.85K | -40.1% |
| Q4 FY2024 | Dec 31, 2024 | $819.39K | – |
| Q3 FY2024 | Sep 30, 2024 | $786.14K | -29.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.03M | -6.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.26M | +13.7% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.12M | -11.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.10M | -3.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.11M | +7.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.05M | -3.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.27M | +21.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.14M | +13.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.04M | +0.5% |
| Q4 FY2021 | Dec 31, 2021 | $1.09M | -6.9% |
| Q3 FY2021 | Sep 30, 2021 | $1.05M | -6.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.00M | -8.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.03M | +5.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.17M | +20.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.12M | +14.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.09M | +32.5% |
| Q1 FY2020 | Mar 31, 2020 | $974.43K | +7.0% |
| Q4 FY2019 | Dec 31, 2019 | $972.46K | -23.0% |
| Q3 FY2019 | Sep 30, 2019 | $984.73K | +8.4% |
| Q2 FY2019 | Jun 30, 2019 | $820.05K | +7.6% |
| Q1 FY2019 | Mar 31, 2019 | $910.37K | +56.2% |
| Q4 FY2018 | Dec 31, 2018 | $1.26M | +72.0% |
| Q3 FY2018 | Sep 30, 2018 | $908.79K | +55.1% |
| Q2 FY2018 | Jun 30, 2018 | $761.89K | +96.9% |
| Q1 FY2018 | Mar 31, 2018 | $582.93K | +71.6% |
| Q4 FY2017 | Dec 31, 2017 | $734.11K | +189.3% |
| Q3 FY2017 | Sep 30, 2017 | $585.83K | – |
| Q2 FY2017 | Jun 30, 2017 | $387.01K | – |
| Q1 FY2017 | Mar 31, 2017 | $339.62K | – |
| Q4 FY2016 | Dec 31, 2016 | $253.74K | – |
See a number that looks wrong?